These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 24239186)
1. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc. Fauber BP; de Leon Boenig G; Burton B; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; Liimatta M; Lockey P; Norman M; Ouyang W; René O; Wong H Bioorg Med Chem Lett; 2013 Dec; 23(24):6604-9. PubMed ID: 24239186 [TBL] [Abstract][Full Text] [Related]
2. A reversed sulfonamide series of selective RORc inverse agonists. van Niel MB; Fauber BP; Cartwright M; Gaines S; Killen JC; René O; Ward SI; de Leon Boenig G; Deng Y; Eidenschenk C; Everett C; Gancia E; Ganguli A; Gobbi A; Hawkins J; Johnson AR; Kiefer JR; La H; Lockey P; Norman M; Ouyang W; Qin A; Wakes N; Waszkowycz B; Wong H Bioorg Med Chem Lett; 2014 Dec; 24(24):5769-5776. PubMed ID: 25453817 [TBL] [Abstract][Full Text] [Related]
3. Identification of tertiary sulfonamides as RORc inverse agonists. Fauber BP; René O; Burton B; Everett C; Gobbi A; Hawkins J; Johnson AR; Liimatta M; Lockey P; Norman M; Wong H Bioorg Med Chem Lett; 2014 May; 24(9):2182-7. PubMed ID: 24685544 [TBL] [Abstract][Full Text] [Related]
4. Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. Fauber BP; René O; de Leon Boenig G; Burton B; Deng Y; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; La H; Liimatta M; Lockey P; Norman M; Ouyang W; Wang W; Wong H Bioorg Med Chem Lett; 2014 Aug; 24(16):3891-7. PubMed ID: 25017032 [TBL] [Abstract][Full Text] [Related]
5. Discovery of biaryls as RORγ inverse agonists by using structure-based design. Enyedy IJ; Powell NA; Caravella J; van Vloten K; Chao J; Banerjee D; Marcotte D; Silvian L; McKenzie A; Hong VS; Fontenot JD Bioorg Med Chem Lett; 2016 May; 26(10):2459-2463. PubMed ID: 27080181 [TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist. Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388 [TBL] [Abstract][Full Text] [Related]
7. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists. Fauber BP; Gobbi A; Savy P; Burton B; Deng Y; Everett C; La H; Johnson AR; Lockey P; Norman M; Wong H Bioorg Med Chem Lett; 2015 Oct; 25(19):4109-13. PubMed ID: 26321361 [TBL] [Abstract][Full Text] [Related]
8. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α. Doebelin C; He Y; Campbell S; Nuhant P; Kumar N; Koenig M; Garcia-Ordonez R; Chang MR; Roush WR; Lin L; Kahn S; Cameron MD; Griffin PR; Solt LA; Kamenecka TM Med Chem; 2019; 15(6):676-684. PubMed ID: 30799793 [TBL] [Abstract][Full Text] [Related]
9. Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity. Gong H; Weinstein DS; Lu Z; Duan JJ; Stachura S; Haque L; Karmakar A; Hemagiri H; Raut DK; Gupta AK; Khan J; Camac D; Sack JS; Pudzianowski A; Wu DR; Yarde M; Shen DR; Borowski V; Xie JH; Sun H; D'Arienzo C; Dabros M; Galella MA; Wang F; Weigelt CA; Zhao Q; Foster W; Somerville JE; Salter-Cid LM; Barrish JC; Carter PH; Dhar TGM Bioorg Med Chem Lett; 2018 Jan; 28(2):85-93. PubMed ID: 29233651 [TBL] [Abstract][Full Text] [Related]
10. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc). Fauber BP; Magnuson S J Med Chem; 2014 Jul; 57(14):5871-92. PubMed ID: 24502334 [TBL] [Abstract][Full Text] [Related]
11. Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand. Marcotte DJ; Liu Y; Little K; Jones JH; Powell NA; Wildes CP; Silvian LF; Chodaparambil JV BMC Struct Biol; 2016 Jun; 16(1):7. PubMed ID: 27246200 [TBL] [Abstract][Full Text] [Related]
12. Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317. Toyama H; Sato S; Shirakawa H; Komai M; Hashimoto Y; Fujii S Bioorg Med Chem Lett; 2016 Apr; 26(7):1817-20. PubMed ID: 26905831 [TBL] [Abstract][Full Text] [Related]
13. Structural States of RORγt: X-ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds. Kallen J; Izaac A; Be C; Arista L; Orain D; Kaupmann K; Guntermann C; Hoegenauer K; Hintermann S ChemMedChem; 2017 Jul; 12(13):1014-1021. PubMed ID: 28590087 [TBL] [Abstract][Full Text] [Related]
14. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293 [TBL] [Abstract][Full Text] [Related]
16. Discovery of 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide analogs as new RORC modulators. Muegge I; Collin D; Cook B; Hill-Drzewi M; Horan J; Kugler S; Labadia M; Li X; Smith L; Zhang Y Bioorg Med Chem Lett; 2015 May; 25(9):1892-5. PubMed ID: 25840886 [TBL] [Abstract][Full Text] [Related]
17. Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists. Wu XS; Wang R; Xing YL; Xue XQ; Zhang Y; Lu YZ; Song Y; Luo XY; Wu C; Zhou YL; Jiang JQ; Xu Y Acta Pharmacol Sin; 2016 Nov; 37(11):1516-1524. PubMed ID: 27374490 [TBL] [Abstract][Full Text] [Related]